Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study

Effect of Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion on Parkinson's Disease-Related Pain: A 6-Month Real-World Longitudinal Study.

Movement disorders clinical practice·2026

Lipid-Related Metabolic Dysregulation Affects Survival in Idiopathic Normal Pressure Hydrocephalus.

Movement disorders clinical practice·2026

Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial.

Parkinsonism & related disorders·2026

Effect of continuous subcutaneous foslevodopa/foscarbidopa infusion on gait in advanced Parkinson's disease: a real-world wearable-based study.

Journal of neurology·2026

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Movement disorders : official journal of the Movement Disorder Society·2026

Comparative efficacy of agomelatine and escitalopram in people with epilepsy and comorbid major depressive disorder: A double-blind randomized controlled trial.

Epilepsy & behavior reports·2026

From consensus to evidence: Bridging the gap in pharmacotherapy for insomnia and sleep dysfunction in Parkinson's disease.

Parkinsonism & related disorders·2026

Why does restless legs syndrome emerge in Parkinson's disease? A state-dependent sensorimotor gating reserve hypothesis.

Parkinsonism & related disorders·2026

Enteric alpha-synuclein pathology in early-onset parkinsonism: Findings in a patient with SCA6.

Parkinsonism & related disorders·2026

Altered IL-23/IL-17A immune axis in Parkinson's disease: An exploratory analysis.

Parkinsonism & related disorders·2026

Depression in the prodromal phase of Parkinson's disease: Clinical manifestations, biomarker evidence, and predictive implications.

Parkinsonism & related disorders·2026

Hierarchical deep learning-radiomics fusion for differentiating Parkinson's disease from atypical Parkinsonism using FP-CIT imaging.

Parkinsonism & related disorders·2026

Pharmacogenomic Markers of Disease Susceptibility and Glucocorticoid Responsiveness in Pemphigus Vulgaris.

Indian dermatology online journal·2026

Glucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction.

Journal of the American Heart Association·2026

Prescribing prevalence and trends of medications with pharmacogenetic implications: a study based on primary care data in Manitoba, Canada.

Pharmacogenomics·2026

From metabolic therapy to addiction care: a clinical pharmacology roadmap for GLP-1 receptor agonists in substance use disorders.

Expert review of clinical pharmacology·2026

Trends in prescriptions and costs of psychotropic drugs in the UK from 2013 to 2023.

BJPsych open·2026

Perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists.

Saudi journal of anaesthesia·2026

Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study

Related Experiment Videos

Related Concept Videos

Effect of Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion on Parkinson's Disease-Related Pain: A 6-Month Real-World Longitudinal Study.

Lipid-Related Metabolic Dysregulation Affects Survival in Idiopathic Normal Pressure Hydrocephalus.

Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial.

Effect of continuous subcutaneous foslevodopa/foscarbidopa infusion on gait in advanced Parkinson's disease: a real-world wearable-based study.

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Comparative efficacy of agomelatine and escitalopram in people with epilepsy and comorbid major depressive disorder: A double-blind randomized controlled trial.

From consensus to evidence: Bridging the gap in pharmacotherapy for insomnia and sleep dysfunction in Parkinson's disease.

Why does restless legs syndrome emerge in Parkinson's disease? A state-dependent sensorimotor gating reserve hypothesis.

Enteric alpha-synuclein pathology in early-onset parkinsonism: Findings in a patient with SCA6.

Altered IL-23/IL-17A immune axis in Parkinson's disease: An exploratory analysis.

Depression in the prodromal phase of Parkinson's disease: Clinical manifestations, biomarker evidence, and predictive implications.

Hierarchical deep learning-radiomics fusion for differentiating Parkinson's disease from atypical Parkinsonism using FP-CIT imaging.

Pharmacogenomic Markers of Disease Susceptibility and Glucocorticoid Responsiveness in Pemphigus Vulgaris.

Glucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction.

Prescribing prevalence and trends of medications with pharmacogenetic implications: a study based on primary care data in Manitoba, Canada.

From metabolic therapy to addiction care: a clinical pharmacology roadmap for GLP-1 receptor agonists in substance use disorders.

Trends in prescriptions and costs of psychotropic drugs in the UK from 2013 to 2023.

Perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists.

Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study

Related Experiment Videos

Related Concept Videos

Related Articles